Atlanta, Georgia 30342

  • Crohn's Disease


The purpose of this study is to determine if increasing the dose and/or dosing frequency of certolizumab pegol (Cimzia) is effective in regaining and optimizing response in patients with moderate to severe Crohn's disease.

Study summary:

This open label study for patients with moderate to severe Crohn's disease will evaluate treatment options to improve capture of initial response and to regain loss of response to certolizumab pegol (Cimzia). It is a 26 week open label clinical trial that may be extended to 52 weeks in patients who respond to treatment during the initial 26 week study. The following dosing options will be tested: 1) Re-induction (one supplemental dose of 400mg) 2) Dose splitting (200mgQ2W) and 3) Dose Escalation (400mg Q2W. The highest dose in the study, 400mg Q2W, has been used in a large phase III trial (WELCOME) without any new safety signals. Efficacy and safety measures will be monitored.


Inclusion Criteria: - ileal and/or colonic Crohn's disease - moderate to severe Crohn's disease Exclusion Criteria: - short bowel syndrome - ostomy - anti-TNF therapy within 4 weeks - prior certolizumab therapy



Primary Contact:

Principal Investigator
Douglas C Wolf, MD
Atlanta Gastroenterology Associates

Lamia S Mereby, BSN
Phone: 404-257-9000 ext. 2142

Backup Contact:

Ashleigh K Arnold, BS
Phone: 404-257-9000 ext. 2138

Location Contact:

Atlanta, Georgia 30342
United States

Lamia S Mereby, BSN
Phone: 404-257-9000

Site Status: Recruiting

Data Source:

Date Processed: September 17, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.